PD-1 ⁽⁴⁾

Recently, Jason Carter, the 48-year-old grandson of former US President Jimmy Carter, described to the public his grandfather's life after entering hospice care. Jason said that the mental state of 99-year-old Jimmy Carter is no longer what it was; the old man cannot be guaranteed…

PD-1 immunotherapy has developed rapidly in recent years. As a new therapy for tumor diseases, it is deeply welcomed by clinicians and patients; oncologists, cancer patients, and their families all place great expectations on it, hoping to use immunotherapy to solve the cancer problem. But…

Ipilimumab, also known as Y-drug or anti-CTLA4 monoclonal antibody, is a recombinant humanized monoclonal antibody developed by Bristol-Myers Squibb that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). Since March 25, 2011, when the US FDA approved Yervoy (3 mg/kg) monotherapy for unresectable or metastatic melanoma, more…

As early as two or three years ago, patients who had used PD-1 began reporting its side effects to me, and I myself have participated in diagnosing and managing some of the adverse effects seen in cancer patients on PD-1. I hesitated for a long…